Rumors swirled in the British press for nearly a decade that Allen hooked up with Oasis frontman Liam Gallagher on an ...

Eli Lilly (NYSE:LLY) announced positive results from a late-stage trial of Omvoh (mirikizumab-mrkz) for patients suffering from moderately to severely active ulcerative colitis. The study demonstrated ...

The company's multibillion-dollar investments in manufacturing in the U.S. are likely to be warmly welcomed by the Trump administration. Eli Lilly's management has already committed to taking action ...

AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer’s agreement to lower its drug prices for Medicaid and a White House decision ...

FILE PHOTO: FA combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

President Donald Trump announced on Sept. 25 that the U.S. will impose a 100% tariff on branded or patented pharmaceutical products that enter the country starting Oct 1. But Eli Lilly, one of ...

Corey Dambacher was working in Oregon when he discovered a type of ribonucleic acid capable of creating unique types of proteins that express themselves on the surfaces of cancer cells. It’s just the ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eli Lilly's massive investment ...